GeoVax Labs, Inc. will present at the Emerging Growth Conference to provide an update on its GEO-CM04S1 program, including the termination of the BARDA contract. CEO David Dodd will lead the presentation, followed by a Q&A session. GeoVax is a biotech company focused on developing vaccines and therapies for infectious diseases and solid tumor cancers.